Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease
| Status: | Completed |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 60 - 90 |
| Updated: | 11/30/-0001 |
| Start Date: | July 2011 |
| End Date: | December 2012 |
| Contact: | Donald A Mahler, M.D. |
| Email: | Donald.a.mahler@hitchcock.org |
| Phone: | 603 650-5533 |
Efficacy of Inhaling Bronchodilator Medications in Patients With Chronic Obstructive Pulmonary Disease Who Have a Low Peak Inspiratory Flow Rate
Some patients with Chronic Obstructive Pulmonary Disease (COPD) report that they are
uncertain whether they achieve clinical benefit using a dry-powder inhaler (DPI). One
possible explanation is that the patient is unable to inhale the dry powder bronchodilator
medication into the lower respiratory tract due to a low peak inspiratory flow rate (PIFR).
A PIFR < 60 l/min is considered to be suboptimal flow for a DPI, including the Diskus
device. The hypothesis of the study is that the FEV1 measured at two hours after inhalation
of the study medication will be higher with arformoterol solution (15 mcg) from a nebulizer
compared with salmeterol dry powder (50 mcg) inhaled from the Diskus.
Inclusion Criteria:
- male or female patient 60 years of age or older; diagnosis of COPD; current or former
smoker; previous or current use of Diskus device; PIFR < 60 l/min using the In-check
DIAL against the resistance of the Diskus device; clinically stable.
Exclusion Criteria:
- any patient who has a concomitant disease that might interfere with study procedures
or evaluation; inability to withhold short-acting and long-acting bronchodilators on
the days of testing
We found this trial at
1
site
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Click here to add this to my saved trials
